Clinical Guide to Ophthalmic Drugs 2017 this 2017 edition of annual Clinical Guide to Ophthalmic Drugs. Although the market has not yielded an avalanche of new drugs to share with our readers this year, we will discuss myriad ways to better use most of the medicines already available. Further, we will offer a variety of clinical pearls to help you provide better care to your patients. The areas of eye care most germane to optometry involve two chronic conditions: dry eye disease and glaucoma. These two disease processes make up more than 50% of our patient population. The two newest drugs that currently, or soon will, grace our therapeutic armamentarium are designed for patients with these conditions: Xiidra (lifitegrast 5% ophthalmic solution) for treatment of signs and symptoms of dry eye disease, approved by the FDA in July 2016; and soon-to-be released Vyzulta (latanoprostene bunod 0.24% ophthalmic solution) for glaucoma, which would be the first nitric oxide-donating prostaglandin F2 analog available for open-angle glaucoma or ocular hypertension.
sponsored link:
Sponsored link:
Disclaimer: THIS SITE COMPLIES WITH DMCA DIGITAL COPYRIGHT LAWS……… .Please bear in mind that we do not own copyrights to this book/software. We’re sharing this with our audience ONLY for educational purpose and we highly encourage our visitors to purchase original licensed software/Books. If someone with copyrights wants us to remove this software/Book, please contact us immediately. You may send an email to smosdr@gmail.com for all DMCA / Removal Requests.
No comments:
Post a Comment